A functional nonsynonymous toll-like receptor 4 gene polymorphism is associated with metabolic syndrome, surrogates of insulin resistance, and syndromes of lipid accumulation
Received 1 April 2009; accepted 16 September 2009. published online 19 November 2009. Corrected Proof
Abstract
Toll-like receptor 4 (TLR4) plays a key role in the activation of innate immune responses. Loss-of-function mutations in TLR4 prevent diet-induced obesity and insulin resistance (IR). We conducted a population cross-sectional study to evaluate whether Asp299Gly (rs4986790) TLR4 gene polymorphism is associated with metabolic syndrome (MS), surrogates of IR, and syndromes of lipid accumulation (SLAs) in Argentinean healthy male subjects. rs4986790 was genotyped in 621 healthy unrelated male blood donors. National Cholesterol Education Program/Adult Treatment Panel III–MS (NCEP/ATP III-MS); SLAs such as enlarged waist elevated triglyceride syndrome (EWET), hypertriglyceridemic waist (HW), and overweight-lipid syndrome (OLS); and surrogates of IR were assessed. The prevalence of MS, OLS, and EWET was significantly higher among Asp299Asp carriers (P < .05). These findings were confirmed using 32 000 bootstrap samples. Surrogate markers of IR were also significantly higher in Asp299Asp carriers (P < .05). Most findings were especially strengthened among individuals with C-reactive protein below the 95th percentile and/or total cholesterol to high-density lipoprotein cholesterol ratio ≥5. This is the first report to find, in Argentinean healthy male blood donors, associations between the Asp299Asp genotype of rs4986790 TLR4 gene polymorphism and high risk for NCEP/ATP III-MS, SLAs, and surrogates of IR. These findings are consistent with previous functional and observational studies showing that Asp299 allele, in comparison with Gly299, is associated with increased TLR4 activation, higher levels of inflammatory cytokines, acute-phase reactants and soluble adhesion molecules, and higher risk of atherosclerosis.
aHumoral Immunity Institute “Prof Ricardo A. Margni” (IDEHU), National Research Council (CONICET) and School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), 1113 Buenos Aires, Argentina
bDivision of Diabetology, Clinical Hospital “José de San Martín,” University of Buenos Aires (UBA), 1120 Buenos Aires, Argentina
cLaboratory of Molecular Biology, Department of Genetics and Molecular Biology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), 1120 Buenos Aires, Argentina
dLaboratory of Lipids and Lipoproteins, Department of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) and National Research Council (CONICET), 1120 Buenos Aires, Argentina
eDepartment of Internal Medicine II, Hospital Clínico San Carlos, 28040 Madrid, Spain
fDivision of Genetics, Clinical Hospital “José de San Martín,” University of Buenos Aires (UBA), 1120 Buenos Aires, Argentina
Corresponding author.
Conflicts of interest/disclosure statement: The authors have nothing to disclose.
Institutional approval: This study was carried out in accordance with the Declaration of Helsinki and was approved by the ethics committee of our institution.